BioIQ Appoints Healthcare Veteran Sean Slovenski as Chief Executive Officer

Former SVP and President for Walmart Health Pivots to Modernize the Testing Industry

ATLANTA--(BUSINESS WIRE)--BioIQ, an aggregator of testing solutions and optimizer of lab capacity for leading employers and health plans, today appointed Sean Slovenski as CEO. As the former head of Walmart Health, Slovenski led critical expansions of the company’s healthcare initiatives. This, coupled with his track record of propelling promising companies into industry powerhouses, makes Slovenski the right leader to scale BioIQ’s testing solutions during COVID-19.

“Sean has unmatched expertise in developing real-world, scalable solutions to fix some of the most complex problems in healthcare,” said Justin Bellante, co-founder, president, and COO. “Overwhelmed by the chaos of COVID-19, the established players have proven that their approach to testing cannot meet this challenge. We’re thrilled to have Sean on our team in this critical moment. His leadership will be transformational for our industry.”

According to a new national survey by four leading academic institutions, most people who are tested for COVID-19 don’t receive results within the recommended 24-48 hour window. Timely results are required to stall the spread of the virus. BioIQ’s national network of labs and advanced analytics deliver faster results along with customized testing solutions for businesses to protect their workforces. Their unique approach can also be applied in the coming immunization crisis.

Over the past six months, seven of the Fortune 50 companies have sought out BioIQ to manage their COVID-19 testing needs. The company also works with more than 40 health plans representing 170 million lives.

“I believe re-inventing the testing industry is the only way out of the pandemic,” said Slovenski. “BioIQ has the right approach to tackle this crisis head-on. The company enables more to be tested faster with reliable results at lower costs. We can help America’s businesses get back to work and, most importantly, keep communities safe from COVID-19.”

Established in 2005, the company provides testing for 20 million lives and is growing. In addition to creating customized testing solutions for the current pandemic crisis, BioIQ is also a leader in the management of testing, analytics, education, and care navigation for colorectal cancer, diabetes, and other conditions that threaten public health.

To learn more about BioIQ’s COVID-19 testing and other services to protect workforces and communities, visit www.bioiq.com.

About BioIQ

BioIQ is modernizing the diagnostic testing industry through a national network of labs and customized solutions that support payors, employers, and consumers. By aggregating testing solutions, optimizing lab capacity, and integrating testing with customers’ needs and strategies, BioIQ ensure resilience and reliability so that employers and payors can protect workforces and members. With its first-of-its-kind health connectivity platform, BioIQ is uniquely positioned at the convergence of population health and the consumerization and retailization of healthcare to drive the shift to value-based care for payers and employers. Since 2005, BioIQ has launched thousands of successful health testing programs serving millions of participants. For more information, visit www.bioiq.com.